Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

Abstract

Due to the lack of a definite diagnosis, a frequent recurrence rate and resistance to chemotherapy or radiotherapy, the clinical outcome for patients with advanced laryngeal cancer has not improved over the last decade. Annexin A2 is associated with the invasion and metastasis of cancer cells. In the present study, it was demonstrated using differential proteomics analysis that Annexin A2 is highly expressed in laryngeal carcinoma tissues and this was confirmed using immunohistochemistry, which demonstrated that the expression of Annexin A2 in laryngeal carcinoma tissues was significantly higher than in healthy adjacent tissue. In addition, its potential predictive value in the prognosis of patients with laryngeal carcinoma was evaluated. The results demonstrated that Annexin A2 expression was significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage. In addition, higher Annexin A2 expression was associated with a poor prognosis of patients with laryngeal cancer. Thus, the results of the present study indicate that Annexin A2 expression is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.

Keywords: Annexin A2; biomarker; laryngeal cancer; prognosis; proteomic.

Figure 1.

Three differential protein spots from two-dimensional polyacrylamide gel electrophoresis gels stained with Coomassie Brilliant Blue were identified as Annexin A2 by differential proteomics analysis and it was determined that this protein was overexpressed in human laryngeal carcinoma tissues.

Figure 2.

Annexin A2 was further identified as positively expressed by immunohistochemical staining analysis with diaminobenzidine staining and its expression was significantly higher in human laryngeal carcinoma tissues compared with adjacent tissues (P=0.001). Magnification, ×100.

Figure 3.

Association between Annexin A2 expression and the overall survival rate of patients with laryngeal carcinoma. The survival rate of patients in the high Annexin A2 expression group was significantly lower than that of patients in the low Annexin A2 expression group (P<0.001).